Maintenance therapy for advanced non-small-cell lung cancer: Ready for clinical practice?

Expert Review of Anticancer Therapy

Volumn 12, Issue 4, 2012, Pages 529-539

  Sibille, Anne ^a   Wauters, Isabelle ^a   Vansteenkiste, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

chemotherapy; maintenance treatment; non small cell lung cancer; review; targeted agents

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO;

ADVANCED CANCER; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PATIENT SELECTION; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS;

EID: 84859802304     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.22     Document Type: Review

References (45)

1. NSCLC meta-Analyses collaborative group. Chemotherapy in non-small cell lung cancer: A meta-Analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 311, 899-909 (1995).
2. Azzoli CG, Temin S, Aliff T et al. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. J. Clin. Oncol. 29, 3825-3831 (2011).
3. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J. Clin. Oncol. 20, 4285-4291 (2002). (Pubitemid 35266288)
4. Scagliotti G, Parikh P, Von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer. J. Clin. Oncol. 26, 3543-3551 (2008).
5. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
6. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
7. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006). (Pubitemid 44917502)
8. Reck M, Von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J. Clin. Oncol. 27, 1227-1234 (2009).
9. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised Phase III trial. Lancet 373, 1525-1531 (2009).
10. O'Byrne KJ, Gatzemeier U, Bondarenko I et al. Molecular biomarkers in non-small-cell lung cancer: A retrospective analysis of data from the Phase 3 FLEX study. Lancet Oncol. 12, 795-805 (2011).
11. Smith IE, O'Brien ME, Talbot DC et al. Duration of chemotherapy in advanced non-small cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J. Clin. Oncol. 19, 1336-1343 (2001). (Pubitemid 32202538)
12. Von Plessen C, Bergman B, Andresen O et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br. J. Cancer 95, 966-973 (2006). (Pubitemid 44606820)
13. Park JO, Kim SW, Ahn JS et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small cell lung cancer. J. Clin. Oncol. 25, 5233-5239 (2007).
14. Felip E, Gridelli C, Baas P et al. Metastatic non-small cell lung cancer: Consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann. Oncol. 22, 1973-1980 (2011).
15. Buccheri G, Ferrigno D, Curcio A et al. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Cancer 63, 428-432 (1989). (Pubitemid 19038453)
16. Socinski MA, Schell MJ, Peterman A et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage IIIB/IV non-small cell lung cancer. J. Clin. Oncol. 20, 1335-1343 (2002). (Pubitemid 34182817)
17. Belani CP, Barstis J, Perry MC et al. Multicenter, randomized trial for stage IIIB or IV non-small cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J. Clin. Oncol. 21, 2933-2939 (2003). (Pubitemid 46621844)
18. Brodowicz T, Krzakowski M, Zwitter M et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A Phase III trial. Lung Cancer 52, 155-163 (2006).
19. Panageas KS, Ben-Porat L, Dickler MN et al. When you look matters: The effect of assessment schedule on progression-free survival. J. Natl Cancer Inst. 99, 428-432 (2007). (Pubitemid 47073565)
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. 92, 205-216 (2000). (Pubitemid 30099779)
21. Julka PK, Doval DC, Gupta S et al. Response assessment in solid tumours: A comparison of WHO, SWOG and RECIST guidelines. Br. J. Radiol. 81, 444-449 (2008). (Pubitemid 351957754)
22. Belani CP, Waterhouse DM, Ghazal H et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 28(Suppl.), Abstract 7506 (2010).
23. Perol M, Chouaid C, Milleron BJ et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 Phase III study. J. Clin. Oncol. 28(Suppl.), Abstract 7507 (2010).
24. Perol M, Zalcman G, Monnet I et al. Final results from the IFCT-GFPC 0502 Phase III study: Maintenance therapy in advanced NSCLC with either gemcitibine (G) or erlotinib (E) versus observation (O) after cisplatin-gemcitabine induction chemotherapy (CT) with a predefined second-line treatment. Ann. Oncol. 21(Suppl. 8), Abstract 370 (2010).
25. Paz-Ares LG, De Marinis F, Dediu M et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J. Clin. Oncol. 29(Suppl.), Abstract 7510 (2011).
26. Cella D, Eton DT, Fairclough DL et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592. J. Clin. Epidemiol. 55, 285-295 (2002). (Pubitemid 34195525)
27. Gridelli C, De Marinis F, Pujol JL et al. Safety, resource use, and quality of life (Qol) results from PARAMOUNT: A phase III study of maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pemetrexed-cisplatin for advanced non-small cell lung cancer. J. Thorac. Oncol. 6, Abstract O11 (2011).
28. Barlesi F, De Castro J, Dvornichenko V et al. Final efficacy outcomes for patients with advanced non-squamous nonsmall cell lung cancer randomized to continuation maintenance with bevacizumab or bevacizumab plus pemetrexed after first-line bevacizumab-cisplatin-pemetrexed treatment. Eur. J. Cancer 47(Suppl. 2), Abstract LBA34 (2011).
29. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small cell lung cancer: Results of the randomized multicenter Phase III trial BMS099. J. Clin. Oncol. 28, 911-917 (2010).
30. Westeel V, Quoix E, Moro-Sibilot D et al. Randomized study of maintenance vinorelbine in responders with advanced non-small cell lung cancer. J. Natl Cancer Inst. 97, 499-506 (2005). (Pubitemid 40590431)
31. Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J. Clin. Oncol. 18, 2354-2362 (2000). (Pubitemid 30415821)
32. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J. Clin. Oncol. 27, 591-598 (2009).
33. Hollen PJ, Gralla RJ, Kris MG et al. Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS). Eur. J. Cancer 29A, 51S-58S (1993).
34. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, Phase 3 study. Lancet 374, 1432-1440 (2009).
35. Miller VA, O'Connor P, Soh C et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27(Suppl.), Abstract 8002 (2009).
36. Kabbinavar FF, Miller VA, Johnson BE et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 28(Suppl.), Abstract 7526 (2010).
37. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled Phase 3 study. Lancet Oncol. 11, 521-529 (2010).
38. Coudert B, Ciuleanu T, Park K et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann. Oncol. 23(2), 88-94 (2011).
39. Zhang L, Shenglin M, Song X et al. Efficacy, tolerability, and biomarker analyses from a Phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). J. Clin. Oncol. 29(Suppl.), Abstract 7511 (2011).
40. Gaafar RM, Surmont V, Scagliotti G et al. A double-blind, randomized, placebo-controlled Phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). J. Clin. Oncol. 28(Suppl.), Abstract 7518 (2011).
41. Dickson R, Bagust A, Boland A et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: A NICE single technology appraisal. Pharmacoeconomics 29, 1051-1062 (2011).
42. Learn PA, Bach PB. Pem and the cost of multicycle maintenance. J. Thorac. Oncol. 5, 1111-1112 (2010).
43. Sun JM, Park JO, Won YW et al. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy. J. Thorac. Oncol. 5, 540-545 (2010).
44. Oxnard GR, Zhao B, Sima CS et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J. Clin. Oncol. 29, 3114-3119 (2011).
45. Peeters L, Anrys B, Sibille A et al. Maintenance therapy: How does my patient feel about it? J. Thorac. Oncol. 6(Suppl.), 183S (2011).